Hybrigenics SA (ALHYG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH82632D
- Pages: 26
- November 2018
- Total Views:1239
- Region : Europe
- GlobalData
- Equity Research Report

Details
Summary
Hybrigenics SA (Hybrigenics) is a biopharmaceutical company that develops new targets and therapies against proliferative and non-cancerous diseases. Its lead product candidate Inecalcitol, is a vitamin D receptor agonist being assessed for various cancer indications including prostate cancer, chronic lymphocytic leukaemia and moderate to severe psoriasis. The company is also investigating the action of deubiquitinating enzymes (DUB) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics' employs its expertise in DUBs to discover and develop new treatments. It also offers specialized scientific services for validating and inhibiting protein interactions in animal, plant or microbiological cells. Hybrigenics is headquartered in Paris, France.
Hybrigenics SA (ALHYG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Hybrigenics Acquires Genomic Division Of Imaxio 11
Equity Offering 12
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For USD 8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For USD 4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For USD 1.9 Million 19
Hybrigenics SA-Key Competitors 20
Hybrigenics SA-Key Employees 21
Hybrigenics SA-Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Apr 26, 2018: Hybrigenics Announces Its Full Year 2017 Results 23
Apr 28, 2017: Hybrigenics fuLL year 2016 resuLts 24
Product News 25
03/26/2018: Hybrigenics broad spectrum inhibitor of Ubiquitin-Specific Proteases shows antiviral activity against human adenoviruses 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List Of Figure
List of Figures
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Hybrigenics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics Acquires Genomic Division Of Imaxio 11
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For USD 8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For USD 4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For USD 1.9 Million 19
Hybrigenics SA, Key Competitors 20
Hybrigenics SA, Key Employees 21
Hybrigenics SA, Subsidiaries 22
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Hybrigenics SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Hybrigenics SA (Hybrigenics) is a biopharmaceutical company that develops new targets and therapies against proliferative and non-cancerous diseases. Its lead product candidate Inecalcitol, is a vitamin D receptor agonist being assessed for various cancer indications including prostate cancer, chronic lymphocytic leukaemia and moderate to severe psoriasis. The company is also investigating the action of deubiquitinating enzymes (DUB) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics' employs its expertise in DUBs to discover and develop new treatments. It also offers specialized scientific services for validating and inhibiting protein interactions in animal, plant or microbiological cells. Hybrigenics is headquartered in Paris, France.
Hybrigenics SA (ALHYG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Hybrigenics Acquires Genomic Division Of Imaxio 11
Equity Offering 12
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For USD 8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For USD 4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For USD 1.9 Million 19
Hybrigenics SA-Key Competitors 20
Hybrigenics SA-Key Employees 21
Hybrigenics SA-Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Apr 26, 2018: Hybrigenics Announces Its Full Year 2017 Results 23
Apr 28, 2017: Hybrigenics fuLL year 2016 resuLts 24
Product News 25
03/26/2018: Hybrigenics broad spectrum inhibitor of Ubiquitin-Specific Proteases shows antiviral activity against human adenoviruses 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List Of Figure
List of Figures
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Hybrigenics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics Acquires Genomic Division Of Imaxio 11
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For USD 8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For USD 4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For USD 1.9 Million 19
Hybrigenics SA, Key Competitors 20
Hybrigenics SA, Key Employees 21
Hybrigenics SA, Subsidiaries 22
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Hybrigenics SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.